Ovarian Cancer Response Scoring (OCRS): Validation of a system to quantify histopathological response to neoadjuvant chemotherapy in high-grade serous ovarian cancer

被引：0
|
作者：
Singh, N. [1 ]
Said, I. [1 ]
Faruqi, A. [1 ]
Gilks, B. [1 ]
Le, N. [1 ]
Boehm, S. [1 ]
机构：
[1] Barts Hlth NHS Trust, Dept Cellular Pathol, London, England
来源：
VIRCHOWS ARCHIV | 2014年 / 465卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
OFP-14-004
引用
下载
收藏
页码：S40 / S40
页数：1
相关论文
共 50 条
  • [31] Tissue is the issue: chemotherapy response score (CRS) is most predictive of response to neoadjuvant chemotherapy in advanced, high grade serous ovarian cancer (HGSOC)
    Knickerbocker, Abbey
    Kuchta, Kristine
    Donaldson, Carolyn
    Moore, Elena Diaz
    Lippitt, Melissa
    Rodriguez, Gustavo
    Watkin, William
    Vogel, Tilley Jenkins
    GYNECOLOGIC ONCOLOGY, 2022, 165 : S10 - S11
  • [32] Tissue is the issue: Chemotherapy response score (CRS) is most predictive of response to neoadjuvant chemotherapy in advanced, high grade serous ovarian cancer (HGSOC)
    Knickerbocker, Abbey
    Kuchta, Kristine
    Donaldson, Carolyn
    Moore, Elena Diaz
    Lippitt, Melissa
    Rodriguez, Gustavo
    Watkin, William
    Vogel, Tilley Jenkins
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S241 - S242
  • [33] Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy
    Lee, J-Y.
    Paik, S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [34] New prognostic index for neoadjuvant chemotherapy outcome in patients with advanced high-grade serous ovarian cancer
    Chuying Huo
    Bin Wu
    Dongdong Ye
    Miaochun Xu
    Shaolin Ma
    Aoshuang Cheng
    Yunyun Liu
    Chunxian Huang
    Yuhao Zhang
    Zhongqiu Lin
    Bowen Li
    Huaiwu Lu
    BMC Cancer, 24 (1)
  • [35] Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy
    Lee, Yong J.
    Kim, Dachan
    Shim, Jung E.
    Bae, Su-Jin
    Jung, Yu-Jin
    Kim, Sora
    Lee, Hanna
    Kim, So H.
    Jo, Su B.
    Lee, Jung-Yun
    Kim, Hyun-Soo
    Paik, Soonmyung
    INTERNATIONAL JOURNAL OF CANCER, 2020, 146 (07) : 1851 - 1861
  • [36] Neoadjuvant treatment as a window to chemotherapy driven alterations to the genome and transcriptome of high-grade serous ovarian cancer
    Javellana, Melissa
    Eckert, Mark
    Stock, Elizabeth
    Chapel, David
    Lastra, Ricardo
    Lengyel, Ernst
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S210 - S210
  • [37] High-grade serous Ovarian Cancer: TP53 Mutations and Platinum Response
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (07)
  • [38] Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer
    Stanske, Mandy
    Wienert, Stephan
    Castillo-Tong, Dan Cacsire
    Kreuzinger, Caroline
    Vergote, Ignace
    Lambrechts, Sandrijne
    Gabra, Hani
    Gourley, Charlie
    Ganapathi, Ram N.
    Kolaschinski, Ivonne
    Budczies, Jan
    Sehouli, Jalid
    Ruscito, Ilary
    Denkert, Carsten
    Kulbe, Hagen
    Schmitt, Wolfgang
    Johrens, Korinna
    Braicu, Ioana
    Darb-Esfahani, Silvia
    NEOPLASIA, 2018, 20 (03): : 280 - 288
  • [39] Phylogenetic and signature analyses predict treatment response in high-grade serous ovarian cancer
    Oikkonen, Jaana
    Li, Yilin
    Alkodsi, Amjad
    Carpen, Olli
    Huhtinen, Kaisa
    Hietanen, Sakari
    Grenman, Seija E.
    Lehtonen, Rainer
    Hautaniemi, Sampsa
    CANCER RESEARCH, 2018, 78 (13)
  • [40] Histopathology and proteomics are synergistic for high-grade serous ovarian cancer platinum response prediction
    Oz Kilim
    Alex Olar
    András Biricz
    Lilla Madaras
    Péter Pollner
    Zoltán Szállási
    Zsofia Sztupinszki
    István Csabai
    npj Precision Oncology, 9 (1)
12345